Atara Biotherapeutics Inc (OQ:ATRA)

Apr 05, 2024 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired e
Mar 28, 2024 08:30 am ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2023, recent business highlight
Feb 29, 2024 09:05 am ET
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (
Feb 28, 2024 04:30 pm ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cel
Feb 14, 2024 09:00 am ET
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Fo
Jan 31, 2024 06:30 pm ET
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercializ
Jan 08, 2024 09:00 am ET
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agreement for the issuance and sale of pre-fund
Jan 08, 2024 08:00 am ET
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Comp
Jan 04, 2024 04:01 pm ET
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, California.
Dec 20, 2023 04:01 pm ET
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the
Dec 11, 2023 12:00 pm ET
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chi
Dec 01, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hire
Nov 29, 2023 06:05 pm ET
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in p
Nov 22, 2023 04:01 pm ET
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.
Nov 10, 2023 04:01 pm ET
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fir
Nov 08, 2023 05:35 pm ET
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressi
Nov 01, 2023 08:30 am ET
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported recent business highlights including an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel®), financial results for the third quarter 2023, and key upcoming catalysts.
Oct 06, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 56,750 restricted stock units of Atara’s common stock to four newly hired
Sep 20, 2023 09:31 am ET
Thinking about buying stock in VinFast Auto, Lilium, Exscientia, Atara Biotherapeutics, or Bird Global?
NEW YORK, Sept. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VFS, LILM, EXAI, ATRA, and BRDS.
Sep 19, 2023 04:01 pm ET
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel
Sep 01, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired e
Aug 31, 2023 04:01 pm ET
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a Cel
Aug 08, 2023 04:01 pm ET
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upco
Aug 04, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 72,000 restricted stock units of Atara’s common stock to two newly hired
Aug 01, 2023 04:01 pm ET
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on T
Jul 31, 2023 04:01 pm ET
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate at the C
Jul 07, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 116,550 restricted stock units of Atara’s common stock to five newly hire
Jun 07, 2023 04:01 pm ET
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fir
Jun 05, 2023 09:00 am ET
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated effectiveness and safety data for tabelecleucel (tab-cel® or
Jun 02, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired e
May 08, 2023 04:01 pm ET
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcom
May 05, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 6,250 restricted stock units of Atara’s common stock to one newly hired e
May 01, 2023 04:01 pm ET
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Mo
Mar 31, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 93,950 restricted stock units of Atara’s common stock to three newly hire
Mar 03, 2023 04:01 pm ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 62,350 restricted stock units of Atara’s common stock to six newly hired
Mar 01, 2023 04:01 pm ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cel
Feb 21, 2023 04:01 pm ET
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fir
Feb 08, 2023 04:01 pm ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlight
Feb 06, 2023 08:00 am ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2022 financial results after market
Feb 03, 2023 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 36,750 restricted stock units of Atara’s common stock to three newly hire
Jan 13, 2023 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired
Jan 04, 2023 04:01 pm ET
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st
Dec 20, 2022 04:33 pm ET
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty
Dec 19, 2022 08:00 am ET
Atara Biotherapeutics Announces Changes to Its Board of Directors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences.
Dec 19, 2022 07:00 am ET
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European Commission (EC) has granted marketing authorization for Ebvallo™ (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transpla
Dec 15, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to Ricardo Fonseca, its new Vice President, Operations.
Dec 12, 2022 10:00 am ET
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated interim analysis and safety results from its Phase 3 multicenter ALLELE study
Dec 02, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 33,150 restricted stock units of Atara’s common stock to five newly hired
Nov 23, 2022 08:00 am ET
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a vir
Nov 09, 2022 04:01 pm ET
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that AJ Joshi, MD, Chief Medical Officer, and Utpal Koppikar, Chief Financial Officer
Nov 08, 2022 04:01 pm ET
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.
Nov 04, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 7,200 restricted stock units of Atara’s common stock to two newly hired e
Nov 01, 2022 04:05 pm ET
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2022 financial results after market close on T
Oct 26, 2022 02:01 am ET
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new magnetic resonance imaging (MRI) biomarker and open-label extension (OLE) clinica
Oct 14, 2022 07:08 am ET
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) approval of EbvalloTM (tabelecleucel) as a monotherapy for treatment of ad
Oct 10, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 8,000 restricted stock units of Atara’s common stock to one newly hired employee. This award w
Sep 29, 2022 09:31 am ET
Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, or Biomerica?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBAI, BBBY, ATRA, SLNG, and BMRA.
Sep 28, 2022 04:01 pm ET
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, today announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel®) for Epstein-Barr virus (EBV)-positive cancers.
Aug 31, 2022 04:01 pm ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cel
Aug 15, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Fulgent, Generac, Atara, and Clariant and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT), Generac Holdings, Inc. (NYSE: GNRC), Atara Biotherapeutics, Inc. (NASDAQ: ATRA), and...
Aug 08, 2022 04:01 pm ET
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlig
Aug 05, 2022 09:00 pm ET
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of Atara stockholders. Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 05, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TuSimple Holdings, Inc. (NASDAQ: TSP), Atara Biotherapeutics, Inc. (NASDAQ: ATRA), Mercury Systems, Inc. (NASDAQ: MRCY), and...
Aug 04, 2022 09:00 pm ET
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of Atara stockholders. Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 04, 2022 04:55 pm ET
ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
Aug 04, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired empl
Aug 03, 2022 04:01 pm ET
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canac
Aug 01, 2022 04:01 pm ET
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on
Jul 28, 2022 05:18 pm ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ:
Jul 14, 2022 05:45 am ET
ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.
NEW YORK, July 14, 2022 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
Jul 12, 2022 04:30 pm ET
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced completion of the planned Interim Analysis (IA) of the ATA188 Phase 2 randomized, placebo-controlled study
Jul 06, 2022 04:01 pm ET
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim A
Jul 01, 2022 07:57 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 31,515 restricted stock units of Atara’s common stock to four newly hired empl
Jun 04, 2022 09:00 am ET
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced EMA regulatory progress and tabelecleucel (tab-cel®) clinical outcomes. Data is reported from t
Jun 03, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired emp
May 19, 2022 04:01 pm ET
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies.
May 06, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 115,059 restricted stock units of Atara’s common stock to 13 newly hired emplo
May 05, 2022 04:01 pm ET
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts.
Apr 29, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to Charlene Banard, its new Executive Vice President, Chief Technical Office
Apr 28, 2022 04:01 pm ET
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2022 financial results after market close on T
Apr 22, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to Brian Robinson, its new Senior Vice President, Global Medical Affairs.
Apr 08, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 37,538 restricted stock units of Atara’s common stock to five newly hired empl
Apr 05, 2022 04:01 pm ET
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announces biopharmaceutical executive Charlene Banard will join as Chief Technical Officer. Charlene will oversee pr
Apr 04, 2022 04:01 pm ET
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acqu
Mar 15, 2022 04:01 pm ET
Atara Biotherapeutics to Host EBV and MS Day
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 – 6:00 p.m. EDT
Mar 04, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 45,040 restricted stock units of Atara’s common stock to nine newly hired empl
Mar 02, 2022 08:00 am ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a pan
Feb 28, 2022 04:05 pm ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2021, recent business highlights and key upcoming ca
Feb 18, 2022 08:00 am ET
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, today reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administration (FDA) of a fatal serious adverse event (SAE) associated wi
Feb 17, 2022 04:01 pm ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after ma
Feb 07, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 31,730 restricted stock units of Atara’s common stock to 10 newly hired employ
Jan 26, 2022 04:30 pm ET
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a s
Jan 24, 2022 11:13 am ET
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today lauded the second high impact study this month solidifying EBV as the primary driver of the dev
Jan 10, 2022 08:30 am ET
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Comp
Jan 07, 2022 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 57,164 restricted stock units of Atara’s common stock to 12 newly hired employ
Jan 06, 2022 10:00 am ET
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
Be The Match BioTherapies and Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced an extension of their collaboration to provide high-quality healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for patients with cancer and autoimmune diseases.
Jan 05, 2022 04:01 pm ET
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will present at
Dec 14, 2021 08:31 am ET
Thinking about buying stock in Katapult, Atara Biotherapeutics, CleanSpark, Li-Cycle, or Lucid Group?
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KPLT, ATRA, CLSK, LICY, and LCID.
Dec 13, 2021 07:15 pm ET
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating t
Dec 09, 2021 08:00 am ET
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new preclinical and preliminary clinical results for ATA2271, a next-generation autol
Dec 03, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 21,438 restricted stock units of Atara’s common stock to seven newly hired emp
Nov 30, 2021 08:30 am ET
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferat
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel®) has been fully
Nov 08, 2021 04:01 pm ET
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate
Nov 05, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 52,474 restricted stock units of Atara’s common stock to 15 newly hired emplo
Nov 04, 2021 09:30 am ET
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE stu
Nov 04, 2021 07:30 am ET
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2021, recent business highlights and key catal
Oct 28, 2021 04:01 pm ET
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on T
Oct 13, 2021 07:30 am ET
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase
Oct 04, 2021 07:30 am ET
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America.
Oct 01, 2021 06:14 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 104,386 restricted stock units of Atara’s common stock to 16 newly hired empl
Sep 29, 2021 03:30 am ET
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the European Committee for
Sep 27, 2021 08:30 am ET
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has gran
Sep 03, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 74,055 restricted stock units of Atara’s common stock to 16 newly hired emplo
Sep 02, 2021 08:30 am ET
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled
Aug 09, 2021 04:02 pm ET
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next
Aug 09, 2021 04:01 pm ET
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutica
Aug 02, 2021 06:00 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 110,626 restricted stock units of Atara’s common stock to 28 newly hired emplo
Aug 02, 2021 08:30 am ET
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 20
Jul 02, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired empl
Jul 01, 2021 04:30 pm ET
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company has joined the
Jun 07, 2021 10:30 am ET
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virt
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel
Jun 04, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara’s common stock to 28 newly hired empl
May 14, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Cokey Nguyen, its S
May 13, 2021 04:01 pm ET
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive
May 10, 2021 08:30 am ET
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Cokey Nguyen, Ph.D. as
May 07, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 229,931 restricted stock
May 04, 2021 04:01 pm ET
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent
Apr 27, 2021 05:51 pm ET
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financi
Apr 02, 2021 04:35 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock
Mar 14, 2021 04:00 pm ET
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis
Mar 09, 2021 04:01 pm ET
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive
Mar 05, 2021 04:01 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of restricted stock units to acquire 40,800
Mar 01, 2021 04:05 pm ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full ye
Feb 18, 2021 04:01 pm ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release fourth quarter and full yea
Feb 08, 2021 09:00 am ET
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
“We are pleased to present key translational data advancing the clinical development of ATA188 and tab-cel®, the most advanced allogeneic T-cell immunotherapy in development. Additional data being presented at TCT also support the further development of tab-cel® in EBV-driven diseases, such as EBV+ acquired and primary immunodeficiency lymphoproliferative diseases (AID-LPD and PID-LPD) for which we’re currently enrolling patients for a clinical study,” said Jakob Dupont, M.D., Head of Global Research & Development at Atara. “These are diseases with few treatmen
Jan 27, 2021 08:31 am ET
Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR.
Jan 19, 2021 04:14 pm ET
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six po
Jan 10, 2021 04:06 pm ET
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Atara’s 2020 progress and key upcoming milestones across the Company’s strategic priorities during a presentation at the 39th Annual J.P. Morgan Healthcare Conference, Wednesday, January 13, 1:30 p.m. PST/4:30 p.m. EST.
Jan 06, 2021 08:30 am ET
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive
Jan 04, 2021 07:30 am ET
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today noted that it has not yet initiated the Biologics License Application (BLA) submission for tab-cel® (tabelecleucel), currently in Phase 3 development for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The Company remains on track to complete the BLA
Dec 08, 2020 09:26 pm ET
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share and, to certain investors, pre-funded warrants to purchase 2,040,816 shares of its common stock at a purchase price of $24.4999 per pre-funded warrant share, which represents the pe
Dec 07, 2020 04:07 pm ET
Atara Biotherapeutics Announces Proposed Offering of Common Stock
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock at the public offering pr
Dec 07, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Oncternal Therapeutics, Fate Therapeutics, or Atara Biotherapeutics?
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ONCT, FATE, and ATRA.
Dec 07, 2020 07:00 am ET
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation
Dec 06, 2020 11:00 pm ET
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.
Nov 16, 2020 04:01 pm ET
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upco
Nov 15, 2020 10:00 am ET
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 15-month
Nov 12, 2020 08:30 am ET
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Mee
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation
Nov 09, 2020 04:01 pm ET
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the third quarter ended Septemb
Nov 02, 2020 04:01 pm ET
Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release third quarter 2020 financial
Sep 14, 2020 08:30 am ET
Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of safety and efficacy data in Epste
Sep 11, 2020 08:00 am ET
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of data from the first part of the ongoing Phase 1
Sep 08, 2020 07:00 am ET
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the In
Sep 01, 2020 07:00 am ET
Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 12-month data from all
Aug 05, 2020 04:01 pm ET
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.
Jul 29, 2020 04:01 pm ET
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results afte
Jun 24, 2020 04:34 pm ET
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that the underwriters of its recently closed underwritten offering of 12,633,039 shares of its common stock and pre-funded warrants to purchase 2,866,961 shares of its common stock have exercised in full their option to purchase an additional 2,325,000 shares of common stock at the public offering price less the und
Jun 17, 2020 08:47 am ET
 Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the first patient has been enrolled in a Phase 1b study of ATA188, a
Jun 05, 2020 04:15 pm ET
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that, due to public health and safety concerns related to the coronavirus (“COVID-19”) pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual
Jun 04, 2020 04:01 pm ET
Atara Biotherapeutics to Participate at Two Upcoming Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Pascal Touchon, the Company’s President and Chief Executive Off
May 27, 2020 01:16 am ET
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funded warrants to purchase 2,866,961 shares of its common stock at a purchase price of $11.3199 per pre-funded warrant share, which represents the per
May 26, 2020 04:05 pm ET
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock. The pre-funded warrants will be offered at the same price per share as the common stock, less the $0.0001 per share exercise price of each pre-fu
May 26, 2020 09:31 am ET
Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?
NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL.
May 26, 2020 07:00 am ET
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 20
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of additional safety and efficacy data from its on
May 21, 2020 09:31 am ET
Thinking about buying stock in Atara Biotherapeutics, Anavex Life Sciences, Boxlight Corp, FuelCell Energy, or Upwork Inc?
NEW YORK, May 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRA, AVXL, BOXL, FCEL, and UPWK.
May 19, 2020 08:30 am ET
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present updated safety and efficacy data from its o
May 18, 2020 04:30 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Jakob Dupont, its Executive Vice Pr
May 15, 2020 09:38 am ET
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that an abstract describing the preclinical safety, improved functio
May 14, 2020 04:05 pm ET
 Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Jakob Dupont, M.D. as Exe
May 11, 2020 04:01 pm ET
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the appointment of immunology and cell & gene therapy
May 06, 2020 04:01 pm ET
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the first quarter ended March 31
Apr 30, 2020 04:01 pm ET
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company will release first quarter 2020 financial results after market close on Wednesday, May 6, 2020. Following the releas
Apr 30, 2020 08:30 am ET
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appointment of biotech and finance industry veteran Ron Renaud as a director and non-executive chair of the board of directo
Apr 22, 2020 08:30 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Amar Murugan, its Senior Vice President, General Counsel.
Apr 02, 2020 08:33 am ET
Company Profile for Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV
Apr 02, 2020 08:30 am ET
Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.
Feb 27, 2020 07:30 am ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the fourth...
Feb 21, 2020 04:00 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards...
Feb 20, 2020 04:00 pm ET
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's...
Feb 19, 2020 04:00 pm ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company will release fourth...
Feb 05, 2020 08:30 am ET
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Commercial...
Jan 12, 2020 02:00 pm ET
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced President and Chief Executive Officer...
Dec 09, 2019 10:00 am ET
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lympho
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today presented long-term clinical results from a...
Nov 26, 2019 04:00 pm ET
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's...
Nov 07, 2019 07:30 am ET
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter...
Nov 06, 2019 09:01 am ET
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoprol
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it will present long-term...
Oct 30, 2019 04:05 pm ET
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its third quarter 2019...
Oct 25, 2019 06:11 pm ET
Atara Biotherapeutics Announces Executive Departures
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the departures of Dr. Christopher...
Sep 13, 2019 06:15 am ET
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m. EDT SOUTH SAN FRANCISCO, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc....
Sep 09, 2019 08:00 am ET
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019, at 3:30 p.m. CEST/ 9:30 a.m. EDT SOUTH SAN FRANCISCO, Calif., Sept....
Aug 28, 2019 04:05 pm ET
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's...
Aug 08, 2019 07:30 am ET
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the second...
Aug 01, 2019 04:00 pm ET
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its second quarter 2019 financial...
Jul 18, 2019 11:52 pm ET
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public...
Jul 18, 2019 04:01 pm ET
Atara Biotherapeutics Announces Proposed Offering of Common Stock
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it has commenced an underwritten...
Jul 16, 2019 07:00 am ET
Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced an updated development plan for the...
Jun 29, 2019 07:00 am ET
Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced initial ATA188 Phase 1 safety results...
Jun 25, 2019 04:05 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to its...
Jun 05, 2019 04:30 pm ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.